After a brief break, AstraZeneca is back at divesting — handing off hypertension meds for $350M

The pharma giant is collecting $350 million from Atnahs Pharma for global commercial rights to a suite of five off-patent hypertension drugs: Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).